Award

Modifying Remdesivir Prodrug Design to Enhance the Active Metabolite Accumulation in the Lung (Resubmission)

Description: Narrative Remdesivir has been approved by the FDA for treating patients with severe COVID-19; however, many patients did not respond adequately to the treatment. The study is to test if a different prodrug design would improve the outcomes of remdesivir treatment.

Funder: National Institute of Allergy and Infectious Diseases

Funding type: research

Funder scheme: R21

Start date: 2022-05-13

End date: 2024-04-30

Investigator: HAOJIE ZHU

Institution: UNIVERSITY OF MICHIGAN AT ANN ARBOR

Topic: COVID-19 Clinical Research Studies

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

Funded outputs count: 3